Sigrid Jusélius Foundation has announced the outcome of the application of Senior Researcher grants in 2021. Dr. Jianwei Li, a group leader at the MediCity Research Laboratory, is one of the five awardees, and will receive 700 000 € to develop nanomaterials for cancer therapy from a systems chemistry perspective.
The Cancer Biology laboratories of Klaus Elenius and Kari Kurppa are looking for a doctoral candidate to join a collaborative project of the two laboratories in the University of Turku, Turku, Finland.
Researchers at the University of Turku, Finland, showed that the antibody treatment reactivates the immune defense in patients with advanced-stage cancer. The treatment alters the function of the body’s phagocytes and facilitates extensive activation of the immune system.
This year, the Elias Tillandz prize for the best scientific paper published in 2019 in BioCity Turku has been awarded to Academician Sirpa Jalkanen and her research group.
The Cancer Drug Resistance laboratory is looking for two doctoral candidates to join a new and exciting research group in the University of Turku, Turku, Finland.
Glucocorticoids, which are widely used as treatment in intensive care, can nearly quadruple the death rate of patients suffering from acute respiratory distress syndrome. Researchers at the University of Turku, Finland, discovered the reason for the higher mortality. The findings are also important in the fight against COVID-19 disease.
Cancer IO is a new cancer immunotherapy focused top-level collaborative research and innovation project that starts as a part of the Business Finland’s Personalized Health Program. With a total funding of 10 million euros, Cancer IO is a significant IO focused Nordic research and innovation program.
New study from researchers in Finland and the United Kingdom reveals that tumors lacking a protein called BAP1 have an ineffective immune reaction against cancer, thus rendering immunotherapies ineffectual, particularly in uveal melanomas (UM). The researchers also discovered that when BAP1 is lost, other molecules will be present in order to support cancer growth. Luckily, some of these molecules can be targeted with existing drugs, which can lead to the development of novel immunotherapies.